Scynexis
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, Scynexis sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).
Scynexis: 13 sponsored US clinical trials, none currently recruiting.
Scynexis sponsors 13 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 11 completed. 7 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Other Emerging Fungi, with 1 trials.
Top-decile sponsor footprint
Scynexis ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
11 of 13 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (84.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
13 total, page 1 of 1
Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp
NCT06954493
A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole
NCT05178862
Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis
NCT05399641
Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)
NCT04029116
Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis
NCT03987620
Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis
NCT03672292
Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303)
NCT03734991
Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES)
NCT03363841
Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis
NCT03253094
Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment
NCT03059992
Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis
NCT02244606
Study of SCY-635, Pegasys and Copegus in Hepatitis C
NCT01265511
Safety, PK and Efficacy of 15 Days of SCY-635 Treatment in Hepatitis C Patients
NCT01290965
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 4 |
| Phase 3 | 7 |
How the Scynexis archive is shaped
13 indexed studies, none listed as recruiting (0% open); 11 completed (85%).
Phase mix: 7 late (III/IV) vs 6 early (I/II) (balanced across stages).
Top condition: Other Emerging Fungi (1 trial), 9 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Scynexis: archived-pipeline peers nationwide
Peers matched on 13 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Scynexis sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 13 archived trials
- Adaptimmune · 13 trials · 0% recruiting
- Agennix · 13 trials · 0% recruiting
- Akili Interactive Labs · 13 trials · 0% recruiting
- Alumis · 13 trials · 8% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Scynexis page
13 registered trials is a research-attention snapshot, not an endorsement of Scynexis or any single study.
- None of Scynexis's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Other Emerging Fungi is the condition Scynexis studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Other Emerging Fungi trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Scynexis pipeline card: 13 registered trials from official public datasets.Report a data error.